A NEW PROSPECT FOR BODY CONTROL ?

Researchers are increasingly investigating retatrutide, a novel medication from Eli Lilly, as a significant advance in body management. Unlike many existing approaches, retatrutide is a dual -action agonist targeting equally GLP-1 and GIP, substances that affect satiety and glucose control . Init